Pub. Date : 2019 Feb
PMID : 30353564
5 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | OBJECTIVES: The aim of this study was to evaluate a possible relationship between DRD2/ANKK1 (rs1800497) and SLC6A3/DAT1 (rs28363170) gene polymorphisms with the response to levodopa (L-DOPA)-therapy in patients with Parkinson"s disease (PD). | Levodopa | solute carrier family 6 member 3 | Homo sapiens |
| 2 | OBJECTIVES: The aim of this study was to evaluate a possible relationship between DRD2/ANKK1 (rs1800497) and SLC6A3/DAT1 (rs28363170) gene polymorphisms with the response to levodopa (L-DOPA)-therapy in patients with Parkinson"s disease (PD). | Levodopa | solute carrier family 6 member 3 | Homo sapiens |
| 3 | OBJECTIVES: The aim of this study was to evaluate a possible relationship between DRD2/ANKK1 (rs1800497) and SLC6A3/DAT1 (rs28363170) gene polymorphisms with the response to levodopa (L-DOPA)-therapy in patients with Parkinson"s disease (PD). | Levodopa | solute carrier family 6 member 3 | Homo sapiens |
| 4 | OBJECTIVES: The aim of this study was to evaluate a possible relationship between DRD2/ANKK1 (rs1800497) and SLC6A3/DAT1 (rs28363170) gene polymorphisms with the response to levodopa (L-DOPA)-therapy in patients with Parkinson"s disease (PD). | Levodopa | solute carrier family 6 member 3 | Homo sapiens |
| 5 | CONCLUSIONS: Clinical and demographic characteristics of Brazilian PD patients and differences in DRD2 and DAT1 genes may to determine individual variations in the therapeutic response to L-DOPA in the Brazilian PD patients. | Levodopa | solute carrier family 6 member 3 | Homo sapiens |